How AIM ImmunoTech Inc. is positioning Ampligen to overcome checkpoint inhibitor resistance in ovarian cancer
Can AIM ImmunoTech Inc.’s Ampligen improve checkpoint inhibitor responses in ovarian cancer? Explore the Phase 2 findings and implications.
Privo’s PRV131 enters first-in-human dosing: Can injectable cisplatin change oral cancer surgery?
Privo Technologies has officially initiated dosing in a Phase 1/2 trial evaluating PRV131, its nanoengineered intratumoral cisplatin injectable, for the treatment of T1–T3 oral squamous cell carcinoma (OSCC). The trial, designated Arm 3 of the CLN-004 study, will explore PRV131 as a neoadjuvant therapy aimed at shrinking tumors before surgery. The announcement marks a pivotal […]